<SEC-DOCUMENT>0001213900-21-011046.txt : 20210223
<SEC-HEADER>0001213900-21-011046.hdr.sgml : 20210223
<ACCEPTANCE-DATETIME>20210223111421
ACCESSION NUMBER:		0001213900-21-011046
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210223
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210223
DATE AS OF CHANGE:		20210223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OptimizeRx Corp
		CENTRAL INDEX KEY:			0001448431
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-BUSINESS SERVICES, NEC [7389]
		IRS NUMBER:				261265381
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38543
		FILM NUMBER:		21663750

	BUSINESS ADDRESS:	
		STREET 1:		400 WATER ST., STE. 200
		CITY:			ROCHESTER
		STATE:			MI
		ZIP:			48307
		BUSINESS PHONE:		248-651-6558

	MAIL ADDRESS:	
		STREET 1:		400 WATER ST., STE. 200
		CITY:			ROCHESTER
		STATE:			MI
		ZIP:			48307
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea136289-8k_optimizerx.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 20%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B><BR> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.25in; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934<BR>
<BR>
</B>Date of Report (Date of earliest event reported): February 23, 2021<BR>
<BR>
<U>OptimizeRx Corporation</U><BR>
(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 33%; text-align: center">Nevada</TD>
    <TD STYLE="padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 32%; text-align: center">001-38543</TD>
    <TD STYLE="padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 33%; text-align: center">26-1265381</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(State or other jurisdiction of incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(I.R.S. Employer Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 66%; text-align: center">400 Water Street, Suite 200, Rochester, MI</TD>
    <TD STYLE="padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 33%; text-align: center">48307</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(Address of principal executive offices)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">Registrant&rsquo;s telephone number, including area code: <U>248.651.6568</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">___________________________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Former name or former address, if changed since
        last report)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="width: 96%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Emerging growth company&nbsp;&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Securities registered pursuant to Section 12(b) of the Act:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; border-bottom: black 1.5pt solid; text-align: center"><B>Title of each class</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: black 1.5pt solid; text-align: center"><B>Trading symbol</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 38%; border-bottom: black 1.5pt solid; text-align: center"><B>Name of each exchange on which registered</B></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">Common Stock</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">OPRX</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Nasdaq Capital Market</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>SECTION 8 &ndash; Other Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 8.01</B></TD><TD><B>Other Events</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On February 23, 2021, we issued a press release announcing that
our senior vice president and principal of agency channels, Angelo Campano, has been named to MM+M&rsquo;s 2021 &lsquo;40 Under
40&rsquo; list for his accomplishments and contributions to the healthcare marketing industry. A copy of the press release is attached
as Exhibit 99.1 to this Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The information in Item 8.01 of this Current
Report on Form 8-K (including Exhibit 99.1) shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the Securities
Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;) or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth
by specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>SECTION 9 &ndash; Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 9.01</B></TD><TD><B>Financial Statements and Exhibits</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; background-color: rgb(204,238,255)">
<TD STYLE="width: 15pt; text-align: right">99.1</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><A HREF="ea136289ex99-1_optimizerx.htm">Press release, dated February 23, 2021</A></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>OptimizeRx Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-bottom: Black 1pt solid; width: 33%">/s/ Douglas Baker</TD>
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="width: 33%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Douglas Baker</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Chief Financial Officer</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Date: February 23, 2021</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><BR> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea136289ex99-1_optimizerx.htm
<DESCRIPTION>PRESS RELEASE, DATED FEBRUARY 23, 2021
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><FONT STYLE="color: Black"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 5pt 0 14pt; text-align: center"><FONT STYLE="color: Black"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 70px; width: 298px"></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><FONT STYLE="color: Black"><B>OptimizeRx&rsquo;s
Angelo Campano Named to MM+M 40 Under 40 List </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><I>List Celebrates
Accomplished Young Talent in Medical Marketing</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="color: Black"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="color: Black"><B>ROCHESTER, Mich. &ndash; February
23, 2021 &ndash; </B>OptimizeRx Corporation (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies,
physicians and patients, announced its senior vice president and principal of agency channels, Angelo Campano, has been named
to MM+M&rsquo;s 2021 &lsquo;40 Under 40&rsquo; list for his accomplishments and contributions to the healthcare marketing industry.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="color: Black">The 40 Under 40 list shines a
light on the young marketers whose leadership, thinking and digital know-how have contributed to the industry&rsquo;s continued
growth under challenging market conditions. The list includes individuals ranging from pharma and biotech companies, medical marketing
agencies, device manufacturers, analytics firms and health media.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="color: Black">The award is sponsored by MM+M,
the media-of-record for pharmaceutical marketing and commercialization delivering the most balanced and relevant coverage of its
subject matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="color: Black">Campano has more than 18 years
of experience leading digital channel partnerships and innovation.<BR>
He has been an innovator and leader in electronic health record (EHR) workflow and hub services. Over the course of his career,
he has established partnerships with more than 245 EHR platforms, 100 specialty pharma partners and five communications partners
to bring life sciences resources to more places at the point-of-care. Campano received PM360&rsquo;s ELITE Innovator Award in
2017 and was inducted into the Medical Advertising Hall of Fame in 2014.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="color: Black">&ldquo;As an industry trailblazer,
Angelo has dedicated his career to bringing innovation to the point-of-care,&rdquo; said OptimizeRx chief commercial officer,
Steve Silvestro. &ldquo;This award reflects the tremendous positive impact he has had on our industry and the companies he has
served. We&rsquo;re fortunate to have an industry leader of Angelo&rsquo;s caliber on our team.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="color: Black">MM+M&rsquo;s GM and editor-in-chief,
Steve Madden, commented: &ldquo;When we started the 40 Under 40 program last year, we were blown away by the volume of smart young
people doing high-caliber work. As they assume greater leadership roles, the industry should feel very secure about its fortunes
in the years ahead.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="color: Black">See the full list of honorees
at www.mmm40under40.com/home.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="color: Black">MM+M will celebrate the 2021 honorees
during a virtual event scheduled for March 25, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>About MM+M</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">First published in 1966 as Medical Marketing
&amp; Media, MM+M is the media brand of record for pharmaceutical marketing and commercialization, delivering the most balanced
and relevant coverage of the growing industry. The title produces an essential mix of online breaking news and analysis combined
with monthly print features &mdash; timely, objective, original editorial content for an executive audience of leaders and thinkers
who work in pharma, medical device, diagnostics and greater healthcare marketing. MM+M also develops conferences and live and
virtual events, and engineers the industry&rsquo;s premier awards program, the MM+M Awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>About OptimizeRx</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><FONT STYLE="color: Black">OptimizeRx is a digital health
company that provides communications solutions for life science companies, physicians and patients. Connecting over half of healthcare
providers in the U.S. and millions of patients through a proprietary network, the OptimizeRx digital health platform helps patients
afford and stay on medications. The platform unlocks new patient and physician touchpoints for life science companies along the
patient journey, from point-of-care, to retail pharmacy, through mobile patient engagement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="color: Black">For more information, follow the
company on&nbsp;Twitter,&nbsp;LinkedIn&nbsp;or visit&nbsp;www.optimizerx.com.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><FONT STYLE="color: Black"><B>Important Cautions Regarding
Forward Looking Statements</B><BR>
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as
amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be
used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking
statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or
revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements
are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual
results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks
and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation,
competition and other material risks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>OptimizeRx&nbsp;Contact</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Doug Baker, CFO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Tel (248) 651-6568 (x807)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">dbaker@optimizerx.com&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>Media Relations Contact</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Maira Alejandra, Media Relations Manager</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Tel (754) 245-7070&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">malejandra@optimizerx.com<U>&nbsp;</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>Investor Relations Contact</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Ron Both, CMA&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Tel (949) 432-7557&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Email Contact</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="color: Black"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !& 2H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V:BBJNHZC
M:Z38RWE],L,$0RSM_GD^U %JDS7FW_":>)_%<[Q^$M-6"T1L?:K@#G\^!]!D
MU-_PCGQ!/[T^)+8/UV8X_P#0,57*!Z)17FK>,/%7A.5!XITY+JS8X^U6X Q^
M(X_ @5WVEZK::SI\=[83++!(.&'4'N".Q'I2:L!<HHHI %%%% !1124 +112
M4 +1110 4444 %%%% !124M !1110 4444 %%%% !14-W,;>SFE4 M&C, >G
M KBQXYOB/^/>V_\ 'O\ &LJE:-/XA.21W5%<-_PG-]_S[VW_ (]_C4L'CJ<.
M/M-I&R=_+8@_K6:Q5)]2>=':455T_4(-3MEGMGW(>"#U!]"*M5T)IJZ+"BBB
MF 4444 %>7^)VE\;?$"#P['(RZ?9?/<%3U(&6/UY"CW)KU"O-/AP/.\;^)[B
M3_6^85_ R-_@*J/<:/1+2T@L+6.VM8DB@B7:B(, "IZ**D1%<VT-W;R07$:2
MPR+M='&0PKS/0Q)X$^(S:)O8Z7J6&@#'.TG[OXY!4^O%>HUYI\50(-:\-W4?
M$XG(!'7 9"/UJH]AH](DECA0O*ZH@ZLQP!2-<1)#YS2HL6,[RP"X]<URWQ/&
M? =\#ZQ_^ABN7\->&;WQOIUI<ZY<2PZ/;1K#:VD1VB0*,%C]2.O7Z4DM+@>B
M1^(='EE\J/5+)I.FT3J3_.M '-<E/\+_  O-;F)=/,1QQ)'*VX>_)(K#TJZU
M#P#XIMM"U&Z>ZTB].+6:0\QG. /;G (Z<@BBR>P'HDUU;VY FGBC)Z!W S^=
M<#X U%?^$C\3_:;P&/[5^[\R;C&Y_NY/3ITKIO$/@S2?$]Q#-J<<KO"I1-DA
M7@G->=^#_!6D:YK6O6M[%*T5C<>7"%D((7<PY]>@IJU@/7HIXIU+0RI(H."4
M8$?I7.Z'H<MAXLU?4'U5;E+H_+;!B3#SGID_R%:/A_PY8>&;-[734=(I)/,8
M.Y8YP!_2N/\ !@ ^*'BHX[_^S4EU$>@RSQ0)OFD2->FYV 'ZTV>\M[6'SKB>
M**+^^[A5_,UQWQ;C$G@A\]KB,_J1_6LWPYX4;QE9V^K^)7EDM]@2SLE<JB(H
MQN/?)QFA+2X'>V>K6&HDBQO;>X*]1%*&(_*IKF[M[.(RW4\4,8_CD<*/S-><
M^-/!=GX<TU=>\.*]C=63JS!')#*3CN?<?49I_A_P^?'[-X@\3%Y('8K:6:.1
M&BC@G\\T[+<9WEGK&G:@Q6ROK:X8?PQ2JQ_(&KM><^+OA[IVG:/+JOA])+&]
MLE\X>5(WS <GJ>#CGBNK\':S)KWA:ROYL><Z;9,="RD@G\<9I-:70BIK>ARW
MWBW2=035%MTM?O6I8YFY],_T-='+-' F^:1(UZ;G8 5Y]XQ /Q2\+''/_P!D
M:[/7-"L_$6FFQU!7: L'(1MIR.G-#Z 6/[2LO^?RW_[^K_C1_:5E_P _EO\
M]_5_QKDF^$_A=5):&X  R29S7&:-X1TOQ+XPD31X9(]#L6'FS,Y8SL#T!/3/
M\AGO3LAGM'6H;F]MK*/S+NXB@3^]*X4?K5#Q+KD7AO0+C4)%#&)<1I_><\*/
MSKCO#_@=O$T::YXOFENI[D;XK;<52-#TX'\A^II)=1'=6FLZ;?OLL[^UG?\
MNQRJQ_(&KM</J_PLT>X@,FCA].O4YBDCD8C/;()S^(JQ\/O$=YJMK=Z;J_\
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M&P>H[+]2?PKI?!/@Z/PK8N97$]_<<SS?^RCV_F:=K;AL0_$_/_"!7^.N8_\
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44 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
